Page last updated: 2024-08-24

gemcitabine and Weight Loss

gemcitabine has been researched along with Weight Loss in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (37.50)29.6817
2010's3 (37.50)24.3611
2020's2 (25.00)2.80

Authors

AuthorsStudies
Brown, J; Correa Ordonez, I; Davis, M; Vanenkevort, E; Varun, S; Wojtowicz, M; Young, A1
Aquilini Mummolo, A; Bruno, G; Cincione, RI; Conteduca, V; Giordano, G; Landriscina, M; Lizzi, V; Losavio, F; Pacilli, M; Piscazzi, A; Senia, T1
Adham, M; Boschetti, G; Castel-Kremer, E; Charlois, AL; Chopin-Laly, X; Comte, B; De Talhouet, S; Graillot, E; Lombard-Bohas, C; Walter, T1
Furuhashi, S; Hiraide, T; Kikuchi, H; Kitajima, R; Kiuchi, R; Konno, H; Morita, Y; Sakaguchi, T; Shibasaki, Y; Takeda, M; Takeuchi, H1
Chen, Y; Gao, L; Hong, C; Hong, Y; Jin, Y; Lu, L; Mao, G; Qin, Z; Su, D; Wei, Y; Wu, G; Ye, X; Yuan, G; Zhao, T; Zhou, H; Zhou, Y1
Dobrila Dintinjana, R; Guina, T; Krznarić, Z1
Arvanitaki, M; De Maertelaere, V; Demols, A; Gay, F; Hendlisz, A; Maréchal, R; Van Laethem, JL1
Davis, MA; Eisbruch, A; Fields, MT; Lawrence, TS; Normolle, D; Orfali, A; Pu, AT1

Other Studies

8 other study(ies) available for gemcitabine and Weight Loss

ArticleYear
Is Weight Loss During Chemotherapy for Pancreatic Cancer Prognostic?
    The American journal of hospice & palliative care, 2023, Volume: 40, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Weight Loss

2023
Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Metastatic Pancreatic Cancer.
    The oncologist, 2023, 09-07, Volume: 28, Issue:9

    Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Nutritional Support; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Retrospective Studies; Weight Loss

2023
An onco-geriatric approach to select older patients for optimal treatments of pancreatic adenocarcinoma.
    Journal of geriatric oncology, 2018, Volume: 9, Issue:4

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Clinical Decision-Making; Deoxycytidine; Female; Gemcitabine; Geriatric Assessment; Humans; Male; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Weight Loss

2018
Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer.
    BMC cancer, 2019, May-02, Volume: 19, Issue:1

    Topics: Aged; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Logistic Models; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Survival Analysis; Tegafur; Treatment Outcome; Weight Loss

2019
CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: An observational study.
    Medicine, 2016, Volume: 95, Issue:52

    Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Keratin-19; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; ROC Curve; Taxoids; Weight Loss

2016
Nutritional and pharmacologic support in patients with pancreatic cancer.
    Collegium antropologicum, 2008, Volume: 32, Issue:2

    Topics: Aged; Antineoplastic Agents; Appetite Stimulants; Deoxycytidine; Female; Gemcitabine; Humans; Karnofsky Performance Status; Male; Megestrol Acetate; Middle Aged; Nutritional Support; Pancreatic Neoplasms; Weight Loss

2008
Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
    Oncology, 2007, Volume: 73, Issue:1-2

    Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Weight Loss

2007
Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine).
    International journal of radiation oncology, biology, physics, 2000, Jun-01, Volume: 47, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Radiation; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Gemcitabine; Head and Neck Neoplasms; Lip; Mice; Mice, Inbred C3H; Mouth Mucosa; Radiation Tolerance; Radiation-Sensitizing Agents; Weight Loss

2000